ArticleGene2009
Internal priming: an opportunistic pathway for L1 and Alu retrotransposition in hominins.
Article in Gene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- The L1-dependant and Pol III transcribed Alu retrotransposon, from its discovery to innate immunity.Molecular biology reports · 2021Review
- Insertion and deletion polymorphisms of the ancientMobile DNA · 2017Article
- Roles for retrotransposon insertions in human disease.Mobile DNA · 2016Review
- Links between Human LINE-1 Retrotransposons and Hepatitis Virus-Related Hepatocellular Carcinoma.Frontiers in chemistry · 2016Review
- Discovery and characterization of Alu repeat sequences via precise local read assembly.Nucleic acids research · 2015Article
- Active human retrotransposons: variation and disease.Current opinion in genetics & development · 2012Review
- Rescuing Alu: recovery of new inserts shows LINE-1 preserves Alu activity through A-tail expansion.PLoS genetics · 2012Article
- LINEs, SINEs and other retroelements: do birds of a feather flock together?Frontiers in bioscience (Landmark edition) · 2012Review
- Alu pair exclusions in the human genome.Mobile DNA · 2011Article
- Pathogenesis of chagas' disease: parasite persistence and autoimmunity.Clinical microbiology reviews · 2011Review
- Heads or tails: L1 insertion-associated 5' homopolymeric sequences.Mobile DNA · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Retrotransposons, specifically Alu and L1 elements, have been especially successful in their expansion throughout primate genomes. While most of these elements integrate through an endonuclease-mediated process termed target primed reverse transcription, a minority integrate using alternative methods. Here we present evidence for one such mechanism, which we term internal priming and demonstrate that loci integrating through this mechanism are qualitatively different from "classical" insertions. Previous examples of this mechanism are limited to cell culture assays, which show that reverse transcription can initiate upstream of the 3' poly-A tail during retrotransposon integration. To detect whether this mechanism occurs in vivo as well as in cell culture, we have analyzed the human genome for internal priming events using recently integrated L1 and Alu elements. Our examination of the human genome resulted in the recovery of twenty events involving internal priming insertions, which are structurally distinct from both classical TPRT-mediated insertions and non-classical insertions. We suggest two possible mechanisms by which these internal priming loci are created and provide evidence supporting a role in staggered DNA double-strand break repair. Also, we demonstrate that the internal priming process is associated with inter-chromosomal duplications and the insertion of filler DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.